Catalog No.
Product Name
Application
Product Information
Citations
-
CK1δ Inhibitor
Casein kinase 1δ-IN-16 is a potent inhibitor of casein kinase 1δ (CK1δ). This compound plays a significant role in the regulation of various cellular processes, making it valuable for investigating pathways associated with neurodegenerative disorders. Researchers can utilize Casein kinase 1δ-IN-16 to explore its potential therapeutic effects and functional mechanisms in related studies. -
CK2 Inhibitor
BMS-135 is a potent and selective ATP-competitive inhibitor of casein kinase 2 (CK2), demonstrating IC50 values of 0.8 nM and 0.3 nM for the CK2α and CK2α′ isoforms, respectively. By mimicking ATP, BMS-135 effectively binds to the active site of CK2, inhibiting its serine/threonine phosphorylation activity. This inhibition results in the suppression of cellular proliferation and exhibits anti-tumor properties. BMS-135 is particularly relevant for research applications in colon cancer studies. -
CK2 Peptide Substrate
Casein Kinase II Substrate is specifically designed for use as a peptide substrate in studies involving casein kinase II (CK2). This substrate can be selectively phosphorylated by CK2, making it a valuable tool for investigating the enzyme's activity and regulatory mechanisms. It is suitable for various research applications, including signal transduction studies and the exploration of phosphoprotein functions in cellular processes. -
CK1δ Inhibitor
CK1δ-IN-1 is a selective inhibitor of casein kinase 1 delta (CK1δ), a key regulator in various signaling pathways. This compound has been demonstrated to exhibit potential therapeutic effects in neurodegenerative diseases, particularly Alzheimer's disease. Its inhibition of CK1δ allows for exploration of its role in modulating disease-related processes and can aid in the development of targeted treatments. -
CK2 Inhibitor
CK2-IN-1 is a potent inhibitor of Casein Kinase 2 (CK2) with an IC50 of 150 nM. This compound plays a crucial role in regulating cell signaling, protein synthesis, and tumor progression. CK2-IN-1 is utilized in research applications focusing on cancer biology, cellular metabolism, and neurodegenerative diseases, thereby providing valuable insights into disease mechanisms and potential therapeutic strategies. -
CK1 Inhibitor
CK1γ-IN-1 is a non-selective inhibitor of casein kinase 1 (CK1) with IC50 values of 780 nM for CK1γ1, 570 nM for CK1γ2, and 990 nM for CK1γ3. This compound is valuable for research applications focused on elucidating the role of CK1γ in various biological processes. Its non-specific binding characteristics allow for exploration of CK1γ-related pathways and interactions in cell signaling studies. -
Selective p38α Inhibitor
AMG-548 hydrochloride is a selective inhibitor targeting p38α with a Ki of 0.5 nM and shows moderate selectivity for p38β (Ki=36 nM), while exhibiting over 1000-fold selectivity against p38γ and p38δ. This compound effectively inhibits TNFα production in whole blood stimulated by LPS, with an IC50 of 3 nM. Additionally, AMG-548 hydrochloride disrupts Wnt signaling through the direct inhibition of Casein kinase 1 isoforms δ and ε, making it a valuable reagent for studies in inflammation and cancer research. -
CK1δ Inhibitor
CK1δ-IN-3 is a selective inhibitor of casein kinase 1δ (CK1δ), a key regulator in various cellular processes. This compound exhibits significant biological activity, making it a valuable tool for investigating the role of CK1δ in neurodegenerative disorders. Researchers can utilize CK1δ-IN-3 to explore therapeutic avenues in conditions where CK1δ dysregulation is implicated. -
Casein Kinase Inhibitor
Casein kinase 1δ-IN-25 is a potent inhibitor of casein kinase 1δ, a key regulator involved in various cellular processes. This compound demonstrates significant biological activity in modulating signaling pathways associated with neurodegenerative disorders, including Alzheimer's disease. It serves as a valuable tool for research aimed at understanding the mechanisms underlying these conditions and exploring potential therapeutic strategies. -
CK1 Inhibitor
Casein kinase 1δ-IN-28 is a selective inhibitor of Casein Kinase 1 (CK1) with an IC50 of 0.0146 μM. This compound demonstrates significant potential for modulating CK1-mediated pathways, making it a valuable tool for studies in cell signaling and cancer research. Additionally, Casein kinase 1δ-IN-28 shows a metabolite rate of 52% in human liver microsomes, indicating its metabolic stability for in vitro applications. -
Casein Kinase Inhibitor
PF-670462 is a selective inhibitor of Casein Kinase I ε/δ, known for its role in modulating circadian rhythms. This compound effectively influences the timing and progression of these rhythms, making it a valuable tool for research into circadian biology and related disorders. Its specificity and potency allow for detailed studies on the regulation of circadian-controlled processes. -
Casein Kinase Inhibitor
Casein kinase 1δ-IN-15 is a potent inhibitor of Casein Kinase 1 δ (CK1δ), demonstrating an IC50 of 0.045 μM. This compound is instrumental in research aimed at elucidating the role of CK1δ in various cellular processes, including cell proliferation and circadian rhythm regulation. Its use in biochemical studies provides valuable insights into the modulation of CK1δ-related pathways, making it a critical tool for exploring therapeutic interventions in cancer and other CK1δ-related diseases. -
Casein Kinase 2 Inhibitor
CHX-3107 is a selective inhibitor of Casein Kinase 2 (CK2), a serine/threonine kinase involved in various cellular processes including cell proliferation and apoptosis. By inhibiting CK2, CHX-3107 disrupts downstream signaling pathways, making it a valuable tool for studying CK2's role in cancer biology and other diseases. This compound is utilized in research applications focused on the modulation of kinase activity and its impact on cellular functions. -
Casein Kinase Substrate
Casein Kinase Substrates 3 is designed as a specific substrate for casein kinases. This compound is utilized in biochemical assays to investigate casein kinase activity and signaling pathways. By enabling the study of phosphorylation events, it aids in the understanding of cellular processes regulated by casein kinases, making it valuable for research in cancer, neurobiology, and metabolic disorders. -
Casein Kinase Inhibitor
Casein kinase 1δ-IN-19 is a selective inhibitor of casein kinase 1δ, a key enzyme involved in various signaling pathways. This compound exhibits potent inhibitory activity, making it valuable for investigating the molecular mechanisms underlying neurodegenerative diseases, including Alzheimer's disease. It serves as an important tool for researchers exploring therapeutic strategies targeting CK1δ in these conditions. -
Casein Kinase 1d Inhibitor
WAY-606344 is an inhibitor of Casein kinase 1δ, a key regulatory enzyme involved in various cellular processes. This compound is primarily investigated for its potential in Alzheimer's disease research, where modulation of kinase activity may impact neurodegenerative pathways. Its application in studying CK1δ signaling can contribute to understanding disease mechanisms and the development of therapeutic strategies. -
CK-1δ Inhibitor
Casein kinase 1δ-IN-5 is a selective inhibitor of casein kinase 1δ, exhibiting an IC50 of 47 nM. This compound demonstrates neuroprotective and anti-inflammatory effects in vitro, making it a valuable tool for studying neurodegenerative diseases. Its ability to modulate CK-1δ activity provides insights into various cellular processes and potential therapeutic applications in neurological research. -
CK1δ Inhibitor
Casein kinase 1δ-IN-17 is a selective inhibitor of casein kinase 1δ (CK1δ). This compound has shown potential in modulating CK1δ activity, which plays a significant role in various cellular processes. Its primary application is in the research of neurodegenerative disorders, where targeting CK1δ may provide insights into disease mechanisms and therapeutic strategies. -
CK2 Inhibtor
CK2-IN-7 is an inhibitor of casein kinase 2 (CK2), a serine/threonine kinase involved in various cellular processes including cell proliferation and apoptosis. This compound exhibits a synergistic effect when used in combination with the structurally distinct CK2 probe, SGC-CK2-1, demonstrating enhanced activity against cancer. CK2-IN-7 is a valuable tool for researchers investigating CK2's role in cancer biology and for exploring therapeutic strategies targeting this pathway. -
Casein Kinase Inhibitor
Casein kinase 1δ-IN-22 is a potent inhibitor of casein kinase 1δ, an enzyme implicated in various cellular processes. This compound is valuable for investigating the role of casein kinase 1δ in neurodegenerative diseases, including Alzheimer's disease. Its inhibitory activity allows for the exploration of cellular signaling pathways and potential therapeutic strategies targeting CK1δ-related disorders. -
CK1δ Inhibitor
Casein kinase 1δ-IN-18 is a selective inhibitor of casein kinase 1δ (CK1δ). This compound is valuable in research focused on neurodegenerative disorders, where CK1δ plays a critical role in various signaling pathways. By inhibiting CK1δ, Casein kinase 1δ-IN-18 can help elucidate the mechanisms underlying these diseases and aid in the development of potential therapeutic strategies. -
CK1 Inhibitor
CK1δ-IN-9 is a potent inhibitor of casein kinase 1 delta (CK1δ) with an IC50 value of 1.4 nM. This compound also demonstrates inhibitory effects on p38α and p38β with IC50 values of 0.25 μM and 0.78 μM, respectively. CK1δ-IN-9 has favorable pharmacokinetic properties, including 70% oral bioavailability and moderate clearance, making it suitable for research applications in kinase signaling pathways and therapeutic potential in related diseases. -
CK2 Inhibitor
CX-5279 is a selective inhibitor of casein kinase 2 (CK2), exhibiting IC50 values of 2.73 nM for nCK2 and 0.91 nM for CK2α. This compound demonstrates variable sensitivity to specific mutations, with altered IC50 values of 13.8 nM, 12.5 nM, and 23.35 nM for mutations at Val66 and Ile174. Although CX-5279 shows limited inhibitory activity against PIM1 (IC50 = 8.52 μM), it has been reported to possess anti-proliferative effects in various cancer cell lines. This reagent is applicable in research focused on pancreatic cancer and leukemia. -
Casein Kinase 1δ Inhibitor
CK1δ-IN-6 is a selective inhibitor of Casein Kinase 1δ (CK1δ), targeting a key enzyme involved in cellular signaling pathways. Its inhibition has been linked to potential therapeutic applications in neurodegenerative diseases, particularly Alzheimer's disease. Research utilizing CK1δ-IN-6 can elucidate the role of CK1δ in cellular processes and its contribution to disease progression, making it a valuable tool for uncovering new insights into Alzheimer's pathology. -
CK II Inhibitor
Tyrphostin AG1112 is a potent inhibitor of casein kinase II (CK II). It demonstrates notable inhibition of the p210bcr-abl tyrosine kinase, with IC50 values of 2 μM for p210bcr-abl, 15 μM for epidermal growth factor receptor (EGFR), and 20 μM for platelet-derived growth factor receptor (PDGFR) in relevant cellular models. This compound is valuable for research investigating cancer signaling pathways and therapeutic interventions targeting kinase activity. -
CK1 Inhibitor
Casein kinase 1δ-IN-31 is a selective inhibitor of casein kinase 1 (CK1), demonstrating potent inhibitory activity against CK1α, CK1δ, and p38α with IC50 values of 196 nM, 17 nM, and 18 nM, respectively. Additionally, this compound inhibits Double Homeobox 4 (DUX4) with an IC50 of 1200 nM. Casein kinase 1δ-IN-31 is primarily utilized in research applications to explore CK1 signaling pathways and their roles in various cellular processes and diseases. -
Casein Kinase Inhibitor
4,5,6,7-Tetrabromo-1H-benzimidazole is a selective inhibitor of casein kinase 2 (CK2), functioning through an ATP-competitive mechanism. This compound has been shown to effectively inhibit CK2 activity, making it a valuable tool for investigating the role of CK2 in various cellular processes. Its primary applications include studies on cell proliferation, apoptosis, and signal transduction pathways. Researchers may utilize this reagent to explore CK2's involvement in cancer and other disease states. -
CK1 Inhibitor
CK1δ-IN-7 is a selective inhibitor of casein kinase 1δ (CK1δ), a crucial mediator in various cellular signaling pathways. This compound exhibits potent inhibition of CK1δ activity, making it a valuable tool for investigating the role of CK1δ in cellular processes such as circadian rhythms, cellular proliferation, and apoptosis. Researchers can utilize CK1δ-IN-7 in studies related to cancer, neurodegenerative diseases, and other pathophysiological conditions linked to CK1δ signaling dysregulation. -
CK1δ Inhibitor
CK1δ-IN-8 is a selective inhibitor of casein kinase 1 delta (CK1δ), a crucial regulator in various cellular signaling pathways. This compound demonstrates significant potential in Alzheimer's disease research by modulating phosphorylation processes linked to protein aggregation and neurodegeneration. Its application may aid in elucidating the molecular mechanisms underlying Alzheimer's and developing therapeutic strategies. -
CK1δ Inhibitor
Casein kinase 1δ-IN-30 is a selective inhibitor of Casein kinase 1δ (CK1δ). This compound demonstrates significant biological activity in modulating CK1δ activity, making it a valuable tool for investigating neurodegenerative diseases and related pathways. Its application in research can enhance understanding of CK1δ's role in cellular processes and potential therapeutic targets in neurodegeneration. -
CK1δ Inhibitor
CK1δ-IN-5 is a selective inhibitor of Casein kinase 1δ (CK1δ), a key enzyme involved in various cellular processes. This compound plays a significant role in the study of neurodegenerative diseases by modulating upstream signaling pathways that may contribute to neuronal dysfunction. Researchers can utilize CK1δ-IN-5 to explore potential therapeutic targets and elucidate the molecular mechanisms underlying these diseases. -
CK1 Inhibitor
CK1-IN-5 is a selective inhibitor of Casein Kinase 1 (CK1). It has been shown to extend the circadian period by inhibiting the activity of AtCKL3 and AtCKL4. This compound is of significant interest in circadian rhythm research and offers potential applications in studies of sleep disorders and metabolic regulation. -
β-catenin Inhibitor
Zolucatetide is a potent inhibitor of β-catenin, demonstrating an IC50 of less than 50 nM. It disrupts the interaction between β-catenin and the T-cell factor (TCF) transcription factor, leading to inhibited cell proliferation and induced cell cycle arrest in sensitive cell lines. In preclinical studies, Zolucatetide exhibits notable anti-tumor efficacy in xenograft models of colon cancer, specifically in COLO320DM cells with APC and TP53 mutations. This compound is valuable for research focused on colon cancer and related pathways. -
β catenin/BCL9 PPI Inhibitor
ZW4864 is a selective inhibitor of the β-catenin/B-Cell lymphoma 9 (BCL9) protein-protein interaction. It demonstrates potent inhibition with a Ki value of 0.76 μM and an IC50 of 0.87 μM. This compound is valuable for research applications targeting the Wnt signaling pathway in cancer biology, particularly in studies related to tumor progression and development. -
β-catenin Inhibitor
NRX-252262 is a potent β-catenin inhibitor that enhances the interaction between β-catenin and its E3 ligase, SCFβ-TrCP, facilitating the degradation of mutant β-catenin. With an EC50 of 3.8 nM, it serves as a valuable tool for studying the Wnt signaling pathway and its implications in various cancers and developmental processes. This compound is useful in research applications focused on β-catenin dysregulation and therapeutic strategies targeting Wnt-mediated pathways. -
β-Catenin Inhibitor
β-Catenin-IN-2 is a potent inhibitor of β-catenin, a key regulator in the Wnt signaling pathway. This compound demonstrates significant biological activity in various cancer models, particularly in the study of colorectal cancer. Research applications include investigating the role of β-catenin in tumorigenesis and exploring potential therapeutic interventions targeting this pathway. -
β-catenin Inhibitor
β-catenin-IN-3 is a selective inhibitor of β-catenin, targeting a cryptic allosteric modulation site with a binding affinity of K D 54.96 nM. This compound effectively reduces the viability of β-catenin-driven cancer cells by promoting degradation of β-catenin through the proteasome pathway. β-catenin-IN-3 is valuable for research applications focused on cancer biology and therapeutic strategies targeting aberrant Wnt signaling. -
β-catenin:β-TrCP Interaction Enhancer
NRX-252114 is a potent enhancer of the β-catenin:β-TrCP interaction, facilitating the binding of phosphorylated β-catenin peptides to the E3 ubiquitin ligase SCFβ-TrCP. With an EC50 of 6.5 nM and a Kd of 0.4 nM, this compound significantly boosts the degradation of mutant β-catenin. NRX-252114 is useful in research applications focused on the Wnt signaling pathway and its implications in cancer biology and developmental processes. -
β-catenin:β-TrCP Interaction Enhancer
NRX-103094 is an enhancer of the β-catenin:β-TrCP interaction, specifically targeting the binding of phospho-Ser33/Ser37 β-catenin to its E3 ligase, SCFβ-TrCP. With an EC50 of 62 nM and a Kd of 0.6 nM, NRX-103094 facilitates this critical protein-protein interaction, making it a valuable tool for research into Wnt signaling pathways and related cellular processes. Its ability to modulate β-catenin stability can aid investigations into various aspects of cellular biology, including cancer research and developmental biology. -
Wnt/β-catenin Signaling Activator
Wnt/β-catenin agonist 2 is a potent activator of the Wnt/β-catenin signaling pathway. This compound effectively stimulates Wnt signaling, making it a valuable tool for investigating the molecular mechanisms underlying diseases associated with aberrant signal transduction. Researchers can utilize this reagent in studies focused on developmental biology, cancer research, and regenerative medicine, where modulation of the Wnt pathway plays a critical role. -
Wnt/β-catenin inhibitor
2,5-Dimethylcelecoxib is a selective Wnt/β-catenin pathway inhibitor that shows promising anticancer activity without inhibiting COX-2. It effectively suppresses cancer cell proliferation by targeting the core elements of this signaling pathway. Additionally, 2,5-Dimethylcelecoxib inhibits T-cell factor-dependent transcriptional activity and downregulates the expression of key Wnt/β-catenin target genes, including cyclin D1 and survivin, making it a valuable tool for cancer research. -
β catenin/BCL9 PPI Inhibitor
ZW4864 free base is a selective inhibitor of the β-catenin/BCL9 protein-protein interaction. It exhibits significant inhibitory activity with a Ki value of 0.76 μM and an IC50 value of 0.87 μM, making it a valuable tool for researching β-catenin signaling pathways. This compound is particularly relevant for studies related to cancer biology and therapeutic strategies targeting aberrant Wnt signaling. -
β-catenin/Tcf PPI Inhibitor
UU-T02 is a selective small-molecule inhibitor targeting the β-catenin/T-cell factor protein-protein interaction (β-catenin/Tcf PPI), exhibiting a Ki value of 1.36 μM. This compound effectively inhibits canonical Wnt signaling pathways, demonstrating significant potential in suppressing the growth of colorectal cancer cells. Its application in research is valuable for understanding Wnt-related mechanisms in cancer biology and developing therapeutic strategies. -
β-catenin/BCL9 Inhibitor
Antitumor agent-172 is a selective β-catenin/BCL9 inhibitor, demonstrating an IC50 of 3.92 μM and a high binding affinity with a Kd of 82 nM. This compound activates T cells and enhances antigen presentation, thereby exhibiting significant antitumor efficacy. It also displays favorable pharmacokinetic properties in mouse models, making it a valuable tool for cancer research and therapy. -
wnt/β-catenin Inhibitor
Teplinovivint is a selective inhibitor of the Wnt/β-catenin signaling pathway. It exhibits significant anti-inflammatory properties and is valuable for research related to tendinopathy and related musculoskeletal disorders. This compound serves as a critical tool for investigating the roles of Wnt signaling in various biological processes and diseases. -
Wnt/β-catenin Signaling Activator
Wnt/β-catenin Agonist 3 is a potent activator of the Wnt/β-catenin signaling pathway. This compound enhances β-catenin-mediated transcriptional activity, making it valuable for research related to bone density disorders such as osteoporosis. Its application in cellular and animal models provides insights into the molecular mechanisms underlying Wnt signaling and offers potential therapeutic avenues for bone-related diseases. -
β-catenin/BCL9 Inhibitor
Antitumor agent-171 is a potent inhibitor of the β-catenin/BCL9 interaction, demonstrating an IC50 value of 1.61 μM. This compound exhibits a strong binding affinity to β-catenin, with a Kd of 0.63 μM, and effectively inhibits the expression of the axin2 gene with an IC50 of 0.84 μM. Additionally, Antitumor agent-171 reduces cell viability in HCT116 cells at an IC50 of 4.39 μM. Its ability to activate T cells and enhance antigen presentation underscores its potential in antitumor applications, with favorable pharmacokinetic properties observed in mouse models. -
β-catenin/Tcf PPI Inhibitor
UU-T01 is a selective inhibitor of the β-catenin/T-cell factor 4 (Tcf) protein-protein interaction, exhibiting a Ki value of 3.14 µM. This compound directly binds to β-catenin, with a dissociation constant (KD) of 0.531 µM. UU-T01 is valuable in research focused on Wnt signaling pathways and their implications in cellular processes such as proliferation and differentiation, offering potential insights into cancer biology and related disorders. -
β-catenin:β-TrCP Interaction Enhancer
NRX-1933 is a β-catenin:β-TrCP interaction enhancer that serves as a molecular glue, facilitating the ubiquitination and subsequent degradation of mutated β-catenin. This compound is particularly relevant for research involving the aberrant activation of the Wnt/β-catenin signaling pathway, providing insights into tumor progression and potential therapeutic strategies. Its ability to promote targeted degradation of dysregulated β-catenin makes NRX-1933 a valuable tool for studies on cancer biology and treatment development. -
β-catenin:β-TrCP Interaction Enhancer
NRX-103095 is an enhancer of the interaction between β-catenin and its E3 ubiquitin ligase, SCFβ-TrCP. This compound significantly increases the binding affinity of the phosphorylated β-catenin peptide (pSer33/Ser37) for β-TrCP, exhibiting an EC50 of 163 nM. NRX-103095 is valuable for research applications focused on the Wnt/β-catenin signaling pathway and its implications in various cellular processes and diseases.
